Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 157Carcinoma, Transitional Cell 56Non-Muscle Invasive Bladder Neoplasms 30Urethral Neoplasms 24Carcinoma, Renal Cell 23Neoplasms 19Kidney Neoplasms 15Pancreatic Neoplasms 14Ovarian Neoplasms 14Neoplasm Metastasis 13Carcinoma, Non-Small-Cell Lung 13Prostatic Neoplasms 12Ureteral Neoplasms 11Urologic Neoplasms 9Colorectal Neoplasms 9Breast Neoplasms 9Lung Neoplasms 7Testicular Neoplasms 6Stomach Neoplasms 6Melanoma 6Sarcoma 5Urothelial Cancer 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Osteosarcoma 4Colonic Neoplasms 4Urogenital Neoplasms 3Triple Negative Breast Neoplasms 3Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3

Interventions

Cisplatin 3Etoposide 2Bleomycin 2Amifostine 2pazopanib 1glucarpidase 1Social Determinants of Health 1Methotrexate 1Gemcitabine 1Chemotherapy, Adjuvant 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Gemcitabine × Genitourinary × Clear all
NCT00006105 2013-09-05

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

University of Chicago

Phase 2 Completed
37 enrolled
Genitourinary

Urinary Bladder Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡